These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3152129)

  • 1. [Clinical pharmacology of nitroglycerin for controlled transdermal administration].
    Rewerski W; Janicki PK
    Pol Arch Med Wewn; 1988; 80(2-3):151-5. PubMed ID: 3152129
    [No Abstract]   [Full Text] [Related]  

  • 2. [Transdermal use of nitroglycerin].
    Kawecka-Jaszcz K; Dubiel JP
    Folia Med Cracov; 1989; 30(1-2):13-21. PubMed ID: 2518362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the clinical effectiveness and adverse effects of transdermal nitroglycerin in the form of plasters in patients with stable coronary disease].
    Kośmicki M; Sadowski Z
    Kardiol Pol; 1988; 31(12):758-65. PubMed ID: 3151499
    [No Abstract]   [Full Text] [Related]  

  • 4. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.
    Nakashima E; Noonan PK; Benet LZ
    J Pharmacokinet Biopharm; 1987 Aug; 15(4):423-37. PubMed ID: 3119815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethanol: water mutually enhanced transdermal therapeutic system II: skin permeation of ethanol and nitroglycerin.
    Berner B; Mazzenga GC; Otte JH; Steffens RJ; Juang RH; Ebert CD
    J Pharm Sci; 1989 May; 78(5):402-7. PubMed ID: 2501473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison versus placebo, in the exercise test, of the efficacy of the transdermal administration of trinitroglycerin in stable coronary insufficiency].
    Gaudy MC; Waynberger M; Mothes P; Mathieu P; Jean-Louis P; Julien J; Serrurier D; Darragon T
    Ann Cardiol Angeiol (Paris); 1987 Nov; 36(9):513-6. PubMed ID: 3122630
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration.
    Han C; Jung P; Sanders SW; Lin ET; Benet LZ
    Biopharm Drug Dispos; 1994 Mar; 15(2):179-83. PubMed ID: 8011969
    [No Abstract]   [Full Text] [Related]  

  • 8. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations.
    Williams RL; Thakker KM; John V; Lin ET; Liang-Gee W; Benet LZ
    Pharm Res; 1991 Jun; 8(6):744-9. PubMed ID: 1905809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a new transdermal nitroglycerin adhesive patch formulation.
    Riedel DJ; Wick KA; Hawkinson RW; Kolars CA; Crowley JK; Armstrong KE; Chang SF; Harrison LI; de Dennis SR
    Clin Ther; 1989; 11(2):225-31. PubMed ID: 2500248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hercon technology for transdermal delivery of drugs.
    Shah KR; Ng S; Zeoli L; Haight V; Matz S; Kydonieus AF
    J Biomater Appl; 1986 Oct; 1(2):239-73. PubMed ID: 3146634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing of controlled-release transdermal dosage forms. Product development and clinical trials.
    Shaw JE; Prevo ME; Amkraut AA
    Arch Dermatol; 1987 Nov; 123(11):1548-56. PubMed ID: 2960274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal nitroglycerin.
    Hutchinson L
    N C Med J; 1985 Apr; 46(4):247-50. PubMed ID: 3921857
    [No Abstract]   [Full Text] [Related]  

  • 13. Warm air convection heating blankets may increase the absorption of transdermal nitroglycerin.
    Roth JV
    Anesthesiology; 1997 May; 86(5):1208-9. PubMed ID: 9158370
    [No Abstract]   [Full Text] [Related]  

  • 14. Transdermal drug delivery: a review of pharmaceutics, pharmacokinetics, and pharmacodynamics.
    Moore L; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1988; 4(4):285-349. PubMed ID: 3133121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific and clinical experience with transdermal nitroglycerin. Panel discussion.
    Am Heart J; 1986 Jul; 112(1):241-5. PubMed ID: 3088965
    [No Abstract]   [Full Text] [Related]  

  • 16. [High-dose transdermal nitroglycerin therapy: loss of effect within 24 hours?].
    Reiniger G; Kraus F; Dirschinger J; Blasini R; Rudolph W
    Herz; 1985 Jun; 10(3):157-62. PubMed ID: 3926612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypotension following administration of sublingual nitroglycerin.
    Cunningham J
    Heart Lung; 1979; 8(2):364. PubMed ID: 106026
    [No Abstract]   [Full Text] [Related]  

  • 18. The clinical use of transdermal delivery devices with nitroglycerin.
    Thompson RH
    Angiology; 1983 Jan; 34(1):23-31. PubMed ID: 6401952
    [No Abstract]   [Full Text] [Related]  

  • 19. A symposium: Transdermal nitroglycerin--maximizing therapeutic efficacy. July 26, 1985, New York, New York.
    Am J Cardiol; 1985 Dec; 56(17):1I-53I. PubMed ID: 3934949
    [No Abstract]   [Full Text] [Related]  

  • 20. The controversy over transdermal nitroglycerin: an update.
    Charash B; Scheidt SS
    Am Heart J; 1986 Jul; 112(1):207-15. PubMed ID: 3088958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.